证券代码：688163 证券简称：赛伦生物 公告编号：2025-019 上海赛伦生物技术股份有限公司2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次会议是否有被否决议案：无 一、会议召开和出席情况 （一）股东大会召开的时间：2025年8月11日 （二）股东大会召开的地点：上海赛伦生物技术股份有限公司（上海市青浦区 华青路1288号）会议室 （三）出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及其持有表决权数量的情 况： ■ （四）表决方式是否符合《公司法》及公司章程的规定，大会主持情况等。 本次股东大会由公司董事会召集，董事长范志和先生主持。本次股东大会以现场方式召开，采用现场投 票与网络投票相结合的方式表决。会议的召集、召开及表决方式符合《公司法》《公司章程》的规定， 会议决议合法、有效。 （五）公司董事、监事和董事会秘书的出席情况 1、公司在任董事9人，出席9人； 2、公司在任监事3人，出席3人； 表决情况： ■ 3、董事会秘书成琼女士现场出席了 ...

证券代码：688163 证券简称：赛伦生物 公告编号：2025-019 上海赛伦生物技术股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 （五） 公司董事、监事和董事会秘书的出席情况 1、 公司在任董事9人，出席9人； 2、 公司在任监事3人，出席3人； 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 8 月 11 日 （二） 股东大会召开的地点：上海赛伦生物技术股份有限公司（上海市青浦区 华青路 1288 号）会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 76 | | --- | --- | | 普通股股东人数 | 76 | | 2、出席会议的股东所持有的表决权数量 | 65,880,183 | | 普通股股东所持有表决权数量 | 65,880,183 | | 3、出席会议的股东所持有表决权数量占公司表决权数量 ...

上海市锦天城律师事务所 关于上海赛伦生物技术股份有限公司 2025 年第一次临时股东大会的 法律意见书 地址：上海市浦东新区银城中路 501 号上海中心大厦 9/11/12 层 电话：021-20511000 传真：021-20511999 邮编：200120 上海市锦天城律师事务所 法律意见书 上海市锦天城律师事务所 关于上海赛伦生物技术股份有限公司 2025 年第一次临时股东大会的法律意见书 致：上海赛伦生物技术股份有限公司 上海赛伦生物技术股份有限公司（以下简称"公司"）2025 年第一次临时股 东大会（下称"本次股东大会"或"会议"）于 2025 年 8 月 11 日在公司会议室召 开。上海市锦天城律师事务所（下称"本所"）经公司董事会聘请，委派吕希菁、 付慧琪律师（下称"经办律师"）出席会议，根据《中华人民共和国证券法》（以 下简称"《证券法》"）、《中华人民共和国公司法》（以下简称"《公司法》"）、 《上市公司股东会规则》（以下简称"《规则》"）和《上海赛伦生物技术股份有 限公司章程》（以下简称"《公司章程》"）的规定，就本次股东大会的召集和召 开程序、出席会议人员资格、召集人的资格、会议的表决程 ...

Group 1 - The company, Siron Biotech (688163.SH), has stated on its interactive platform that it has not conducted any research related to HIV vaccines [1]

上海赛伦生物技术股份有限公司 2025 年第一次临时股东大会会议资料 证券代码：688163 证券简称：赛伦生物 上海赛伦生物技术股份有限公司 2025 年第一次临时股东大会 会议资料 2025 年 8 月 上海赛伦生物技术股份有限公司 2025 年第一次临时股东大会会议资料 上海赛伦生物技术股份有限公司 2025 年第一次临时股东大会会议资料 目 录 | 2025 年第一次临时股东大会会议须知 1 | | --- | | 年第一次临时股东大会会议议程 3 2025 | | 2025 年第一次临时股东大会议案 5 | | 议案一：关于取消监事会、变更经营范围、修订《公司章程》及其附件并办理 | | 工商变更登记的议案 5 | | 议案二：关于修订和制定公司部分治理制度的议案 7 | 上海赛伦生物技术股份有限公司 2025 年第一次临时股东大会会议资料 上海赛伦生物技术股份有限公司 2025 年第一次临时股东大会会议须知 为了维护上海赛伦生物技术股份有限公司（以下简称"公司"、"本公司"、 "赛伦生物"）全体股东的合法权益，确保股东大会的正常秩序和议事效率，保 证股东大会的顺利进行，根据《中华人民共和国公司法》 ...

料 上海赛伦生物技术股份有限公司 2025 年第一次临时股东大会会议资 证券代码：688163 证券简称：赛伦生物 上海赛伦生物技术股份有限公司 2025 年第一次临时股东大会 会议资料 2025 年 8 月 上海赛伦生物技术股份有限公司 2025 年第一次临时股东大会会议资 料 上海赛伦生物技术股份有限公司 2025 年第一次临时股东大会会议资料 目 录 | 2025 年第一次临时股东大会会议须知 1 | | --- | | 2025 年第一次临时股东大会会议议程 3 | | 2025 年第一次临时股东大会议案 5 | | 议案一：关于取消监事会、变更经营范围、修订《公司章程》及其附件并办理 | | 工商变更登记的议案 5 | | 议案二：关于修订和制定公司部分治理制度的议案 7 | 料 上海赛伦生物技术股份有限公司 2025 年第一次临时股东大会会议资 上海赛伦生物技术股份有限公司 2025 年第一次临时股东大会会议须知 为了维护上海赛伦生物技术股份有限公司（以下简称"公司"、"本公司"、 "赛伦生物"）全体股东的合法权益，确保股东大会的正常秩序和议事效率，保 证股东大会的顺利进行，根据《中华人民共和国公 ...

Core Insights - The report highlights that the total salary of A-share listed company secretaries in 2024 reached 4.086 billion yuan, with an average annual salary of 754,300 yuan [1] - Over 21% of company secretaries earn more than 1 million yuan annually, indicating a significant portion of high earners in this role [1] Salary Distribution - The average annual salary for company secretaries in the biopharmaceutical sector is 1.01 million yuan, with the distribution of salaries as follows: below 500,000 yuan (15%), 500,000-1,000,000 yuan (41%), 1,000,000-2,000,000 yuan (38%), 2,000,000-3,000,000 yuan (4%), and above 3,000,000 yuan (2%) [5] - The top five highest-paid company secretaries have salaries of 3.2565 million yuan, 2.5345 million yuan, 2.2809 million yuan, 1.9265 million yuan, and 1.89 million yuan, with their tenure at the companies ranging from less than one year to 15 years [7] Age and Educational Background - The age distribution of company secretaries shows that those aged 40-50 constitute 61%, while those over 50 account for 15%, and those under 30 make up 6% [1][3] - The educational background indicates that 52% hold a bachelor's degree, 44% have a master's degree, and only 2% possess a doctoral degree, with the latter represented by just one individual [3] Investor Engagement - There is a significant variance in the number of investor meetings held by companies, with 43% of companies hosting fewer than 10 meetings annually, while only 2% have more than 1,000 meetings [9] - The five companies with the highest number of investor meetings are reported to have 1,500, 777, 681, 549, and 504 meetings, respectively [9]

Core Points - The company, Shanghai Serum Bio-Technology Co., Ltd., was established as a joint-stock company in accordance with the Company Law and other relevant regulations [1][2] - The company was approved for public offering of 27.06 million shares on January 25, 2022, and listed on the Shanghai Stock Exchange on March 11, 2022, under the stock code 688163 [2][3] - The registered capital of the company is RMB 108.22 million [2] - The company aims to adopt advanced and practical technologies and scientific management methods to enhance economic efficiency and provide satisfactory returns to investors [3][4] Company Structure - The company is a permanent joint-stock company with a legal representative being the chairman [2][3] - The company has established a Communist Party organization to conduct party activities [3][4] Business Scope - The company is engaged in the production and import/export of pharmaceuticals and medical devices, as well as internet information services related to pharmaceuticals and medical devices [4][5] Share Issuance - The company's shares are issued in the form of stocks, with each share having a par value of RMB 1 [6][7] - The total number of shares issued at the establishment of the company was 60 million, and the current total number of issued shares is 108.22 million [6][7] Shareholder Rights and Responsibilities - Shareholders have rights to dividends, voting, and other benefits proportional to their shareholdings [11][12] - Shareholders are obligated to comply with laws and the company's articles of association, and they cannot withdraw their capital except as legally permitted [16][17] Governance and Meetings - The company holds annual and extraordinary shareholder meetings, with specific procedures for calling and conducting these meetings [48][49] - The board of directors is responsible for convening shareholder meetings and must ensure compliance with legal and regulatory requirements [52][53] Financial Transactions - Significant transactions, including guarantees and financial assistance, require shareholder approval if they exceed certain thresholds [46][47] - The company must disclose relevant financial information in its annual and semi-annual reports [20][21]

Core Viewpoint - The internal audit system of Shanghai Sailun Biotechnology Co., Ltd. aims to standardize and enhance the quality of internal audit work, ensuring effective risk management and financial information integrity [2][3]. Group 1: General Principles - The internal audit system is established in accordance with relevant laws and regulations, including the Audit Law of the People's Republic of China and the Shanghai Stock Exchange's guidelines for listed companies [2]. - The system applies to all departments, subsidiaries included in the consolidated financial statements, and significant equity investees [2]. Group 2: Audit Committee and Personnel - The Board of Directors establishes an Audit Committee to guide and supervise the internal audit system's implementation [3]. - The internal audit personnel must possess relevant professional knowledge and maintain their competency through continuous education [3][4]. Group 3: Responsibilities of the Audit Committee - The Audit Committee is responsible for guiding the establishment and implementation of the internal audit system and reviewing the annual internal audit work plan [4][5]. - The Committee must report on the progress and quality of internal audit work to the Board of Directors [5]. Group 4: Responsibilities of the Audit Department - The Audit Department evaluates the effectiveness of internal controls and compliance of financial information across the company and its subsidiaries [5][6]. - The department must report at least quarterly to the Audit Committee on the execution of the internal audit plan and any issues discovered [6][7]. Group 5: Implementation of Internal Audit Work - The Audit Department conducts audits based on business processes and evaluates the effectiveness of internal controls related to financial reporting [6][7]. - The department must submit an internal control evaluation report to the Board at least annually, detailing the purpose, scope, and conclusions of the evaluation [7][8]. Group 6: Audit Work Procedures - The Audit Department is required to prepare an annual audit work plan, which must be approved by the Audit Committee before implementation [10][11]. - After completing the audit, the audit team must compile a report that includes the audit scope, findings, and recommendations [10][11]. Group 7: Assessment and Rewards - The company must establish a mechanism for evaluating the performance of internal audit personnel, rewarding those who perform well and penalizing those who violate regulations [12][13]. - Internal audit personnel found to have committed violations may face administrative or economic penalties based on the severity of the offense [12][13].

Core Points - The implementation rules for the cumulative voting system aim to enhance corporate governance and protect the interests of minority shareholders in Shanghai Sailun Biotechnology Co., Ltd [1][2] - The cumulative voting system allows shareholders to allocate their voting rights in a flexible manner during the election of multiple directors [1][2] - The rules specify the nomination process for director candidates, including qualifications and the requirement for written consent from nominees [6][9] Group 1: General Provisions - The cumulative voting system is defined as a voting method where shareholders can distribute their voting rights among multiple candidates during the election of two or more directors [1] - The implementation rules are established in accordance with relevant laws and regulations, including the Company Law and the Articles of Association of the company [1][2] - The rules apply specifically when electing or replacing two or more directors, excluding cases where only one director is elected or replaced [1][2] Group 2: Nomination of Director Candidates - The board's nomination committee is responsible for reviewing the qualifications of director candidates and presenting a list to the board for approval [6][7] - Shareholders holding more than 1% of voting shares can propose new candidates up to 10 days before the shareholders' meeting [7] - Investor protection organizations can request to act on behalf of shareholders to nominate independent directors [8] Group 3: Voting Process - The voting process must clearly inform shareholders about the cumulative voting method prior to the election [4][5] - Each shareholder's voting rights are calculated based on their shareholding multiplied by the number of directors to be elected [4][5] - The voting must be conducted in a manner that allows shareholders to either concentrate or distribute their votes among candidates [5] Group 4: Election of Directors - The results of the voting must be announced, and candidates are ranked based on the total votes received [6][7] - A candidate must receive more than half of the valid voting rights present at the meeting to be elected [6][7] - If there are ties in votes, a second round of voting may be conducted to determine the elected candidates [7][8] Group 5: Miscellaneous Provisions - Any matters not covered by these rules will be governed by relevant laws and the company's Articles of Association [8] - The rules will take effect upon approval by the shareholders' meeting [8] - The board of directors is responsible for interpreting these rules and any amendments must be approved by the shareholders [8]